Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Wave Life Sciences first quarter 2025 earnings conference call. At this time, all participants are in the listen-only mode. As a reminder, this call is being recorded and webcasted. After today's presentation, there'll be an opportunity to ask questions. To ask a question, you may press star and one on your touchtone telephone. To withdraw your question, you may press star and two. I now turn the call over to Kate Roche, Vice President, Investor Relations and Corporate Affairs. Please go ahead. Thank you, Operator, and good morning to everyone on the call. Earlier this morning, we issued a press release outlining our first quarter 2025 earnings update, including progress updates for obesity and AATB clinical trials. Joining me today with prepared remarks are Dr. Paul Volno, President and Chief Executive Officer, Dr. Eric Engelson, Chief Scientific Officer, and Kyle Moran, Chief Financial Officer. The press release issued this morning is available on the investor section of our website, www.wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings. We undertake no obligation to update or revise any forward-looking statements for any reason. I'd now like to turn the call over to Paul. Thanks, Kate. Good morning, and thank you all for joining us on today's call. For over a decade, we've been relentlessly committed to unlocking the broad potential o...